ArticleNature microbiology2025
Deep learning reveals antibiotics in the archaeal proteome.
Article in Nature microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- TACTIC: A transfer learning framework to predict drug interactions in emerging pathogens.Cell reports methods · 2026Article
- From sequence space to ecological function: microbiome-derived antimicrobial peptides as community effectors and therapeutic leads.Essays in biochemistry · 2026Review
- Artificial Intelligence-Driven Antimicrobial Peptide Discovery: Prediction, Generation, Mining and Optimization.Probiotics and antimicrobial proteins · 2026Review
- Carotenoids of Halophilic Archaea: Production, Properties and Biotechnological Applications.Probiotics and antimicrobial proteins · 2026Review
- Marine Antimicrobial Peptides: From Ocean Biodiversity to Genome Mining, Multi-Omics Discovery, and Biotechnological Innovation in the Battle Against Antimicrobial Resistance.Probiotics and antimicrobial proteins · 2026Review
- Chitosan-Based Composite Film Containing Cell-Free Supernatant ofGels (Basel, Switzerland) · 2026Article
- Antimicrobial peptides for tuberculosis in a post-antibiotic era: from in vitro promise to therapeutic potential.npj antimicrobials and resistance · 2026Review
- Deep learning reveals antimicrobial peptides within prions.Nature microbiology · 2026Article
- Encrypted immunity mediated by peptides.PLoS biology · 2026Review
- AllTheBacteria: a community resource empowers biology and discovers novel peptide antibiotics.bioRxiv : the preprint server for biology · 2026Article
- Eco-technological potential of salinity-driven functional specialization in Indian solar salterns revealed by integrated culturomics and whole-metagenome profiling.BMC microbiology · 2026Article
- Harnessing artificial intelligence for antimicrobial discovery and optimization.Current opinion in microbiology · 2026Review
- Pharmaceutical Peptides: From Synthesis and Mechanistic Pharmacology to Future Biologic Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Arctic deep-sea hydrothermal microbiomes as a natural niche for novel antimicrobial peptides.BMC microbiology · 2026Article
- The Extreme Environment Microbiome Catalog (EEMC): a global resource for microbial diversity and antimicrobial discovery.Nature communications · 2026Article
- β-Hairpin Antimicrobial Peptides: Class Diversity and Sequence Analysis.ACS infectious diseases · 2026Review
- Navigating the promise and pitfalls of artificial intelligence.Nature microbiology · 2026Article
- Article
- Article
- The Pharmaceutical Industry in 2025: An Analysis of FDA Drug Approvals from the Perspective of Molecules.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antimicrobial resistance is one of the greatest threats facing humanity, making the need for new antibiotics more critical than ever. While most antibiotics originate from bacteria and fungi, archaea offer a largely untapped reservoir for antibiotic discovery. In this study, we leveraged deep learning to systematically explore the archaeome, uncovering promising candidates for combating antimicrobial resistance. By mining 233 archaeal proteomes, we identified 12,623 molecules with potential antimicrobial activity. These peptide compounds, termed archaeasins, have unique compositional features that differentiate them from traditional antimicrobial peptides, including a distinct amino acid profile. We synthesized 80 archaeasins, 93% of which showed antimicrobial activity in vitro against Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Enterococcus spp. Notably, in vivo validation identified archaeasin-73 as a lead candidate, significantly reducing A. baumannii loads in mouse infection models, with effectiveness comparable to that of established antibiotics such as polymyxin B. Our findings highlight the potential of archaea as a resource for developing next-generation antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.